Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ICH Consults On Supporting Multi-Regional Trials, Non-Clinical Evaluation Of Anticancer Drugs

Executive Summary

The International Council on Harmonisation has endorsed draft versions of two new guidelines – one on conducting multi-regional clinical trials and the other on supporting the non-clinical evaluation of anticancer medicines. The ICH is now seeking stakeholder feedback on both documents.

You may also be interested in...



New ICH Q&A To Support Uptake Of 'Vague' Safety Guideline For Anticancer Drugs

All parties that have used the ICH S9 guideline on the non-clinical evaluation of anticancer medicines have

Japan Builds Asia Links Through New AMED Programs

In line with similar initiatives by Japan on other regulatory fronts, the country's Agency for Medical Research and Development is building up its partnerships and presence in Asia.

ICH: India, Mexico And Russia Among New Observers; Benefit-Risk Guideline Adopted

India, Mexico, Singapore, South Korea, Russia and Taiwan are among the latest countries to become observers at the International Council for Harmonisation, which has been seeking to establish itself as a 'truly global platform' since undergoing major structural reforms last year1.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS118814

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel